TG Therapeutics Details BRIUMVI ENABLE and ENHANCE Data at AAN 2026
TG Therapeutics will present ENABLE real-world Phase 4 results and ENHANCE modified dosing data for BRIUMVI in relapsing multiple sclerosis at the American Academy of Neurology 2026 meeting in Chicago. The ENABLE study examines real-world effectiveness, safety and tolerability, while ENHANCE evaluates optimized IV dosing approaches.
1. AAN 2026 Presentations
TG Therapeutics will present new data for BRIUMVI on April 22 at the American Academy of Neurology 2026 annual meeting in Chicago, featuring two poster presentations on real-world experience and dosing regimen updates.
2. ENABLE Study Insights
The ENABLE Phase 4 observational study provides real-world clinical experience in adults with relapsing multiple sclerosis initiating ublituximab, highlighting effectiveness, safety and tolerability in routine practice settings.
3. ENHANCE Study Updates
The ENHANCE study offers safety and tolerability data on a modified IV dosing regimen of ublituximab, providing insights into optimized treatment schedules and potential benefits in managing relapsing MS.
4. BRIUMVI Mechanism and Indications
BRIUMVI is a glycoengineered anti-CD20 monoclonal antibody designed for efficient B-cell depletion at low doses and is approved for adults with clinically isolated syndrome, relapsing-remitting and active secondary progressive multiple sclerosis.